Filtered By:
Source: Clinical Prostate Cancer
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 128 results found since Jan 2013.
The Complexity of Treatments and the Multidisciplinary Team-A Rare Case of Long-Term Progression-Free Survival in Prostate Cancer until Development of Liver and Brain Metastases
CONCLUSIONS: Brain metastases are an unfavorable prognostic factor in prostate cancer. The therapeutic options developed in recent years allow the improvement of survival.PMID:37685646 | DOI:10.3390/jcm12175579
Source: Clinical Prostate Cancer - September 9, 2023 Category: Cancer & Oncology Authors: Roxana-Andreea Rahnea-Nita Laura-Florentina Rebegea Alexandru Nechifor Cristian Mare ș Radu-Valeriu Toma Alexandru-Rares Stoian Anda-Natalia Ciuhu Liliana-Florina Andronache Georgiana Bianca Constantin Gabriela Rahnea-Nita Source Type: research
A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer
CONCLUSION: In Asian mHSPC patients, upfront ABI + ADT was associated with better PFS than DOC + ADT, with no significant OS difference. PSA kinetics may help stratify the prognosis for treatment intensification. Toxicity profiles were different, with a higher rate of toxicity-related treatment discontinuation in the DOC group.PMID:37604745 | DOI:10.1016/j.clgc.2023.07.012
Source: Clinical Prostate Cancer - August 21, 2023 Category: Cancer & Oncology Authors: Benjamin H W Lam Vivian H M Tsang M P Lee Kuen Chan Tsz Chim Liu Brian Y H Ng Barry B W Wo K C Leung Wing Ho Mui Tim Wai Chan Martin Ho Ching Lam Steven W K Siu Darren M C Poon Source Type: research
Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?
Clin Genitourin Cancer. 2023 Aug 7:S1558-7673(23)00185-4. doi: 10.1016/j.clgc.2023.08.002. Online ahead of print.ABSTRACTIn recent years, several systemic therapies have been introduced for metastatic hormone-sensitive prostate cancer, including androgen deprivation therapy (ADT) combined with docetaxel (Doc) and/or new-generation androgen receptor signaling inhibitors (ARSI). Trials evaluating ADT + ARSI have consistently demonstrated an overall survival (OS) benefit for doublet therapy over ADT alone. Similarly, the STOPCaP meta-analysis showed an OS benefit in favor of ADT + Doc versus ADT alone. ARSI, Doc, and ADT have...
Source: Clinical Prostate Cancer - August 20, 2023 Category: Cancer & Oncology Authors: Noelia Sanmamed Juan G ómez-Rivas David Buchser Miguel Montijano Mar ía Antonia Gómez-Aparicio Victor Duque-Santana Lisselott Torres Thomas Zilli Piet Ost Fernando L ópez-Campos Felipe Cou ñago Source Type: research
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: AAP + C was safe with improved rPFS, OS duration, and a higher proportion of PSA declines. This suggests that AAP + C given earlier rather than sequentially may benefit some men. Further work is needed to identify this population.PMID:37582240 | DOI:10.1200/JCO.22.02639
Source: Clinical Prostate Cancer - August 15, 2023 Category: Cancer & Oncology Authors: Susan F Slovin Karen Knudsen Susan Halabi Renee de Leeuw Ayesha Shafi Praneet Kang Steven Wolf Bin Luo Anuradha Gopalan Tracy Curley Mark Fleming Ana Molina Celina Fernandez Kevin Kelly Source Type: research
The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer
CONCLUSION: There is noteworthy disparity in clinical practice across current study sites, however most have expressed an interest in participation in the forthcoming STAMPEDE2 trial.PMID:37507278 | DOI:10.1016/j.clon.2023.07.009
Source: Clinical Prostate Cancer - July 28, 2023 Category: Cancer & Oncology Authors: H Abdel-Aty L O'Shea C Amos L C Brown E Grist G Attard N Clarke W Cross C Parker M Parmar N Vas As N James Source Type: research
Novel Approaches in the Systemic Management of High-Risk Prostate Cancer
Clin Genitourin Cancer. 2023 Jun 18:S1558-7673(23)00140-4. doi: 10.1016/j.clgc.2023.06.001. Online ahead of print.ABSTRACTLocally advanced prostate cancer comprises approximately 20% of new prostate cancer diagnoses. For these patients, international guidelines recommend treatment with radiotherapy (RT) to the prostate in combination with long-term (2-3 years) androgen deprivation therapy (ADT), or radical prostatectomy in combination with extended pelvic lymph node dissection (PLND) as another treatment option for selected patients as part of multimodal therapy. Improvements in overall survival with docetaxel or an androg...
Source: Clinical Prostate Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Maria Antonia G ómez-Aparicio Fernando L ópez-Campos Antonio Jos é Lozano Xavier Maldonado Bego ña Caballero Juan Zafra Vladamir Suarez Elena Moreno Stefano Arcangeli Marta Scorsetti Felipe Cou ñago Source Type: research
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
CONCLUSION: Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occurred.PMID:37290035 | DOI:10.1200/JCO.23.00233
Source: Clinical Prostate Cancer - June 8, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Se Hoon Park Jeffrey C Goh Sang Joon Shin Jae Lyun Lee Niven Mehra Ray McDermott N úria Sala-Gonzalez Peter C Fong Richard Greil Margitta Retz Juan Pablo Sade Patricio Yanez Yi-Hsiu Huang Stephen D Begbie Rustem Airatovich Gafanov Source Type: research
Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening
Sci Rep. 2023 Jun 3;13(1):9043. doi: 10.1038/s41598-023-35950-7.ABSTRACTEnzalutamide, docetaxel, and cabazitaxel treatment resistance is a major problem in metastatic castration resistant prostate cancer (mCRPC), but the underlying genetic determinants are poorly understood. To identify genes that modulate treatment response to these drugs, we performed three genome-wide CRISPR/Cas9 knockout screens in the mCRPC cell line C4. The screens identified seven candidates for enzalutamide (BCL2L13, CEP135, E2F4, IP6K2, KDM6A, SMS, and XPO4), four candidates for docetaxel (DRG1, LMO7, NCOA2, and ZNF268), and nine candidates for ca...
Source: Clinical Prostate Cancer - June 3, 2023 Category: Cancer & Oncology Authors: Jakob Haldrup Simone Weiss Linn éa Schmidt Karina Dalsgaard S ørensen Source Type: research
Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
J Clin Oncol. 2023 Jun 2:JCO2300723. doi: 10.1200/JCO.23.00723. Online ahead of print.ABSTRACTThe Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.For generation...
Source: Clinical Prostate Cancer - June 2, 2023 Category: Cancer & Oncology Authors: Jeremiah Wala Paul Nguyen Mark Pomerantz Source Type: research
